Phase 3 N=64 Estrogen and Fear in PTSD
PTSD
Primary: Change in Amygdala Activation as Measured by Functional Magnetic Resonance Imaging (fMRI) Blood Oxygen Level Dependent (BOLD) Signal — 0.534; -0.0037 beta weights
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=100 Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Influenza.
Acute Respiratory Viral Infections · Human Influenza
Primary: Efficacy: Number of Participants -- Absence of Objective Symptoms -- Overall — 0; 0; 0; 0 Participants — p=0.5547
Phase 3 N=71 Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)
Pediatric Acute-Onset Neuropsychiatric Syndrome
Primary: Percentage Change in CY-BOCS Score From Baseline to Week 9 — 12.1; 31.1 Percentage Change at Week 9 to Baseline — p=0.0718
Phase 3 N=381 Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
Irritable Bowel Syndrome With Constipation · Functional Constipation
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs). — 37; 15; 4; 31 Participants
Phase 3 N=221 A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management
Analgesia Disorder · Pain
Primary: Pain Assessment Calculated as the Area Under the Curve of VAS Pain Intensity Scores Through 48 Hours After Surgery — 209.93; 253.53 VAS score*hour — p=<0.01
Phase 3 N=600 Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD
Neovascular Age-related Macular Degeneration
Primary: Mean Change in BCVA From Baseline in the Study Eye at the End of 12 Months — 11.17; 11.14 Letters
Phase 3 N=272 Study of LAU-7b for the Treatment of Long COVID in Adults
Long COVID
Primary: Change From Baseline in Physical Component Summary (PCS) of the Medical Outcomes Study Short-Form-36 (SF-36) at Week 12 — 29.47; 29.90; 30.06; 1.94 score on a scale…
Phase 3 N=1,060 Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Uterine Cervical Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator — 47.6; 47.5 Months — p=0.0004
Phase 3 N=3,208 Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older
Influenza
Primary: Percentage of Subjects With Seroconversion Antibody Titer — 47.1; 36.8; 63.8; 37.3 percentage of participants
Phase 3 N=444 A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.4; -10.0 Units on a scale — p==0.670
Phase 3 N=60 Virtual Reality Treatment for Emerging Adults With ADHD
Attention Deficit Hyperactivity Disorder
Primary: Objective On-Task Assessment Algorithm — .86; .62; .83; .83 percentage of time focused
Phase 3 N=151 Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
Agitation · Dementia
Primary: Absolute Change From Baseline in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score for the First Episode of Agitation — -5.7; -7.5; -5.4 score on…
Phase 3 N=305 A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Study Discontinuation — 153; 77; 16; 0 Participants
Phase 3 N=877 An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs) — 139; 160; 342; 37 Participants
Phase 3 N=137 ENAC Blockade and Arterial Stiffness
Overweight and Obesity · Insulin Resistance
Primary: Carotid Femoral Pulse Wave Velocity — 7.25; 6.80; 7.12; 6.81 m/s